Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Multicenter, Open-label, Phase 1 Dose-Escalation Study of LZM009 in Subjects With Advanced Solid Tumors

NCT03286296 is registered in ClinicalTrials.gov with Livzon Pharmaceutical Group Inc. as lead sponsor.

NCT NCT03286296
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03286296 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Multicenter, Open-label, Phase 1 Dose-Escalation Study of LZM009 in Subjects With Advanced Solid Tumors
Lead sponsor
Livzon Pharmaceutical Group Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 21, 2017
Completion date
April 23, 2019
Enrollment
30 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor